Previous close | 8.9000 |
Open | 8.0408 |
Bid | 0.0000 x N/A |
Ask | 0.0000 x N/A |
Day's range | 8.0408 - 8.0408 |
52-week range | 8.0408 - 8.0408 |
Volume | |
Avg. volume | N/A |
Market cap | N/A |
Beta (5Y monthly) | 0.91 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.3780 |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN OR THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. (Ålesund, 1 July 2022) Hofseth Biocare ASA ("HBC" or the "Company") has resolved to effect a contemplated private placement of new shares, after the close of trading on Oslo Bø
Roger Hofseth has today, 6 May 2022, bought 45,000 shares at an average price of NOK 3.7764 per share. Roger Hofseth is CEO and primary insider of Hofseth BioCare ASA. After the transaction, Mr. Hofseth owns 200,000 shares privately and 51,500,000 shares through his a wholly owned company RH Industri AS, totalling 51,700,000 shares and corresponding to 14.45 % of the outstanding shares in Hofseth BioCare ASA. Correction: Notification Form This information is subject to the disclosure requirement
Roger Hofseth has today, 6 May 2022, bought 45,000 shares at an average price of NOK 3.7764 per share. Roger Hofseth is CEO and primary insider of Hofseth BioCare ASA. After the transaction, Mr. Hofseth owns 200,000 shares privately and 51,500,000 shares through his a wholly owned company RH Industri AS, totalling 51,700,000 shares and corresponding to 14.45 % of the outstanding shares in Hofseth BioCare ASA. This information is subject to the disclosure requirements pursuant to Section 5-12 of